Catalyst Pharmaceuticals Announces Third Quarter 2020 Financial Results and Provides Business UpdateGlobeNewsWire • 11/09/20
Catalyst Pharmaceuticals to Hold Third Quarter 2020 Financial Results and Corporate Update Conference Call and Webcast on Tuesday, November 10th, 2020GlobeNewsWire • 11/02/20
Catalyst Pharmaceuticals Announces Filing of Patent Infringement Actions Against Jacobus Pharmaceuticals and PantherRxGlobeNewsWire • 10/19/20
Catalyst Pharmaceuticals Has Potential To Push Higher If They Can Overcome Current HeadwindsSeeking Alpha • 10/14/20
Catalyst Pharmaceuticals Announces Ruling on Lawsuit against the FDA and Intent to AppealGlobeNewsWire • 09/29/20
Catalyst Pharmaceuticals Looks Cheap, but Few Catalysts for Massive Upside24/7 Wall Street • 09/24/20
KYE Pharmaceuticals and Catalyst Pharmaceuticals Challenge Health Canada’s Decision to Overlook Firdapse® Data ExclusivityGlobeNewsWire • 08/26/20
Catalyst Pharmaceuticals and KYE Pharmaceuticals Announce Agreement to Make Firdapse® (amifampridine phosphate) Available to LEMS Patients in CanadaGlobeNewsWire • 08/18/20
Catalyst Pharmaceuticals, Inc. (CPRX) CEO Patrick McEnany on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/11/20
Catalyst Pharmaceuticals Announces Notice of Allowance of a U.S. Patent Application for "Methods of Administering 3,4-Diaminopyridine"GlobeNewsWire • 08/11/20
Catalyst Pharmaceuticals Announces Second Quarter 2020 Financial Results and Provides Business UpdateGlobeNewsWire • 08/10/20
Catalyst Pharmaceuticals’ Firdapse® (amifampridine phosphate) Receives Marketing Approval in Canada for Patients with LEMSGlobeNewsWire • 08/06/20